Mebicar

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Mebicar
Mebicar.svg
Systematic (IUPAC) name
1,3,4,6-Tetramethyltetrahydroimidazo[4,5-d]imidazole-2,5(1H,3H)-dione
Clinical data
Legal status
  • US: Not approved
Identifiers
CAS number 10095-06-4
ATC code ?
PubChem CID 122282
ChemSpider 109042
Chemical data
Formula C8H14N4O2 
Mol. mass 198.222 g/mol

Mebicar (mebicarum) is an anxiolytic medication produced by Latvian pharmaceutical company Olainfarm and sold in the Russian Federation under the brand name Adaptol.[1] It is not approved for use in the United States or European Union.

Mebicar has an effect on the structure of limbic-reticular activity, particularly on hypothalamus emotional zone, as well as on all 4 basic neuromediator systems – γ aminobutyric acid (GABA), choline, serotonin and adrenergic activity. Mebicar decreases the brain noradrenaline level, exerts no effect on the dopaminergic systems, increases the brain serotonin level, and does not elicit cholinolytic action.[2]

Mebicar purportedly has anti-anxiety (anxiolytic) properties.[2][3][4][5][6] It is also used to aid smoking cessation.[1] In addition Mebicar may be useful in the treatment of ADHD symptoms.[7] In contrast with typical anxiolytic medication like benzodiazepines Mebicar is non-habit forming, non-sedating and does not impair motor function.[3][1]

References[edit]

  1. ^ a b c Adaptol product summary http://olainfarm.lv/en/prescription-drugs/adaptol-3
  2. ^ a b Val'Dman, AV; Zaikonnikova, IV; Kozlovskaia, MM; Zimakova, IE (1980). "Characteristics of the psychotropic spectrum of action of mebicar". Biulleten' eksperimental'noi biologii i meditsiny 89 (5): 568–70. PMID 6104993. 
  3. ^ a b Val'Dman, A. V.; Zaikonnikova, I. V.; Kozlovskaya, M. M.; Zimakova, I. E. (1980). "A study of the spectrum of psychotropic action of mebicar". Bulletin of Experimental Biology and Medicine 89 (5): 621. doi:10.1007/BF00835799. 
  4. ^ Mkrtchian, VR; Kozhokova, LZ (2012). "Adaptol--verges of possible". Likars'ka sprava / Ministerstvo okhorony zdorov'ia Ukrainy (5): 125–33. PMID 23534281. 
  5. ^ Chutko, LS; Rozhkova, AV; Sidorenko, VA; Surushkina, SIu; Tursunova, KB (2012). "Generalized anxiety disorder: Psychosomatic aspects and treatment approaches". Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov \i] Vserossiiskoe obshchestvo psikhiatrov 112 (1): 40–4. PMID 22678674. 
  6. ^ Chutko, LS; Surushkina, SIu; Nikishena, IS; Iakovenko, EA; Anisimova, TI; Kuzovenkova, MP (2010). "Asthenic disorders in children". Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov \i] Vserossiiskoe obshchestvo psikhiatrov 110 (11 Pt 1): 26–9. PMID 21183919. 
  7. ^ Chutko, LS; Surushkina, SIu; Nikishena, IS; Iakovenko, EA; Anisimova, TI; Sergeev, AV (2009). "Adaptol in the treatment of ADHD". Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov \i] Vserossiiskoe obshchestvo psikhiatrov 109 (8): 45–8. PMID 19738569.